Myriad Genetics Inc (MYGN)

Add to Watchlists
Create an Alert
Quickflows
18.61 -1.04  -5.29% NASDAQ Feb 24, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All MYGN News

News

View All Events

Events

Date Type Description
05/07/2020 16:30 EDT Misc Myriad Genetics Inc Third Quarter Earnings Conference Call in 2020
05/07/2020 Earnings Myriad Genetics Inc Third Quarter Earnings in 2020 Release
02/06/2020 16:30 EST Misc Myriad Genetics Inc Second Quarter Earnings Conference Call for 2020
02/06/2020 Earnings Myriad Genetics Inc Second Quarter Earnings in 2020 Release
12/05/2019 08:00 MST Misc Myriad Genetics Inc Annual General Meeting for 2019
11/04/2019 16:30 EST Misc Myriad Genetics Inc First Quarter Earnings Conference Call in 2020
11/04/2019 Earnings Myriad Genetics Inc First Quarter Earnings in 2020 Release
08/13/2019 16:30 EDT Misc Myriad Genetics Inc Fourth Quarter Earnings Conference Call in 2019
08/13/2019 Earnings Myriad Genetics Inc Fourth Quarter Earnings in 2019 Release
08/13/2019 Misc Myriad Genetics Inc Annual Report in 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 813.40M
Total Expenses (TTM) 842.50M
Net Income (TTM) -26.20M

Balance Sheet View Statement

Total Assets (Quarterly) 1.578B
Total Liabilities (Quarterly) 501.00M
Shareholders Equity (Quarterly) 1.077B

Cash Flow Statement View Statement

Cash from Operations (TTM) 52.00M
Cash from Investing (TTM) -13.60M
Cash from Financing (TTM) -48.40M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.myriad.com
  • Investor Relations URL: https://myriad.com/news-center/investor-information/
  • HQ State/Province: Utah
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: May. 07, 2020
  • Last Earnings Release: Feb. 06, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 18.61
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
F000013C6A FT Biotechnology 44 F CA 2.49%
FQLGNX FT Biotechnology 43 RE 2.25%
HSVRX Harbor Small Cap Value Admin 1.79%
FENTDX FT Biotechnology 41 RE 1.69%
FVUSA0016E Thrivent Mid Cap Stock 1.63%
PSCH Invesco S&P SmallCap Health Care ETF 1.56%
VSMVX Vanguard S&P Small-Cap 600 Val Idx Instl 0.56%
VIOV Vanguard S&P Small-Cap 600 Value ETF 0.56%

Comparables

Edit
ZGNX Zogenix Inc
RMD ResMed Inc
MRK Merck & Co Inc
HAE Haemonetics Corp
ASRT Assertio Therapeutics Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.